Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00453999
Status:
COMPLETED
Last Update Posted:
2015-02-12
First Post:
2007-03-27
Brief Title:
Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
Sponsor:
BioCryst Pharmaceuticals
Organization:
BioCryst Pharmaceuticals
Study Overview
Official Title:
Phase II Multicenter Randomized Double-Mask Double-Dummy Study Comparing Efficacy and Safety of Intravenous Peramivir Once Daily Versus Oral Oseltamivir Twice Daily in Adults With Acute Serious or Potentially Life-Threatening Influenza
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study has been designed as a randomized double-blind controlled study to evaluate the efficacy and safety of two once daily intravenous peramivir regimens 200 mg and 400 mg versus oral oseltamivir phosphate 75 mg twice daily in hospitalized subjects with acute serious or potentially life threatening influenza Study treatments will be provided for up to 5 consecutive days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None